Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment

Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment

Spontaneous hepatic decompensation was observed in 7 of 383 patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving treatment with interferon and ribavirin. Multivariate analysis identified the following risk factors: didanosine use (odds ratio [OR]...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2005-12, Vol.41 (12), p.1806-1809
Hauptverfasser: Bani-Sadr, Firouzé, Carrat, Fabrice, Rosenthal, Eric, Piroth, Lionel, Morand, Patrice, Lunel-Fabiani, Françoise, Bonarek, Mojgan, de Verdiere, Nathalie Colin, Pialoux, Gilles, Cacoub, Patrice, Pol, Stanislas, Perronne, Christian
Format: Artikel
Sprache:eng
Schlagworte:
Adult
AIDS
Antiretroviral drugs
Antiretrovirals
Antiviral Agents - adverse effects
Biological and medical sciences
Cirrhosis
Drug therapy
Drug Therapy, Combination
Female
Fibrosis
Hepacivirus
Hepatitis
Hepatitis C - complications
Hepatitis C virus
HIV
HIV Infections - complications
HIV/AIDS
Human immunodeficiency virus
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infections
Infectious diseases
Interferon-alpha - adverse effects
Liver
Liver cirrhosis
Liver Failure - chemically induced
Male
Medical sciences
Middle Aged
Polyethylene Glycols
Predisposing factors
Recombinant Proteins
Ribavirin - adverse effects
RNA
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral hepatitis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Spontaneous hepatic decompensation was observed in 7 of 383 patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving treatment with interferon and ribavirin. Multivariate analysis identified the following risk factors: didanosine use (odds ratio [OR], 8.8; 95% confidence interval [CI], 1.2–102.3; P
ISSN:1058-4838
1537-6591
DOI:10.1086/498312